Well, out of the blue another asset of TAUG raises its hand. The Aegea test now has been validated and it can identify different mutations.
If I understand that correctly, Aegea can tell the different mutations of corona through PCR tests using traditional PCR equipment.
Right now, more expensive and complicated tests are being done on a few samples compared to the number of monthly tests through sequencing. There are over 350,000 tests in the US alone right now.
Has anyone listened to the PFE CEO, he thinks if it is needed within weeks, PFE can recode the RNA vaccines to be effective against this new variant if the previous vaccines are not efficacious.
What would a test kit be worth that could identify a specific mutation on every PCR test? My bet is quite a bit?
In fact, I would not be surprised if Aegea Biotechnologies becomes worth 100's of millions of dollars. If so TAug's investment in Aegea could be valued more than the current market cap of TAUG.
I do not like Biocept or its CEO Nall, I think he is a dirtbag penny stock scammer, but since BIOC holds the licensing rights to Aegea's test it seems like a no-brainer to buy. They were barely doing $2 mil in annual cancer screenings and now book about $15 million a quarter in Covid testing. Out of the blue, Quest is now going to start using Biocept's cancer screening tests in January 2023. Quest does quite a of.....COVID Testing. Biocept is located right next to Thermal Fisher, a worldwide top 70 company in market cap. new EUA rules require the manufacturer to be able to produce 500,000 tests a week. Perhaps Aegea is grandfathered in under the old rules. In any event, a very big manufacturing partner is needed.
Why would Nall state that they were not commercializing the test at this time? Very Odd since on the same day Aegea stated they were in talks with the FDA.
"US public health labs sequencing 4 times as many coronavirus specimens now compared to a year ago"
From CNN's Jacqueline Howard
As full disclosure, this is not investment advice to buy BIOC. That company burned me pretty well earlier. I bought calls because I think there is upside because the stock price is low, and it minimizes risk. However, they could expire worthless. It doesn't make sense to validate a test that is better than the other ones on the market and not get it into production immediately.
As far as TAUG the Aegea investment is interesting.
